Oltipraz [64224-21-1]

Shimozono R, Asaoka Y, Yoshizawa Y, et al. Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model. Mol Pharmacol. 2013 Jul;84(1):62-70. PMID: 23592516. Yu Z, Shao W, Chiang Y, et al. Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 [corrected](NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice. Diabetologia. 2011 Apr;54(4):922-34. Erratum in: Diabetologia. 2011 Apr;54(4):989. PMID: 21161163. Lee WH, Kim YW, Choi JH, et al. Oltipraz and dithiolethione congeners inhibit hypoxia-inducible factor-1alpha activity through p70 ribosomal S6 kinase-1 inhibition and H2O2-scavenging effect. Mol Cancer Ther. 2009 Oct;8(10):2791-802. PMID: 19789218. Morsy GH. Parasitological and histo-pathological studies on schistosomiasis mansoni infected mice and treated with praziquatel and/or oltipraz. J Egypt Soc Parasitol. 2009 Aug;39(2):687-701. PMID: 19795775. Merrell MD, Jackson JP, Augustine LM, et al. The Nrf2 activator oltipraz also activates the constitutive androstane receptor. Drug Metab Dispos. 2008 Aug;36(8):1716-21. PMID: 18474683.